|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2010-05-12 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2009-09-24 |
|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2008-12-16 |
A multi-centre, randomised phase 2 clinical trial of early salvage radiotherapy versus surveillance on the incidence of biochemical recurrence after radical prostatectomy for men with prostate cancer, incorporating clinical and imaging-based risk stratification.
Multicentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid Is Needed For Analgesia
The purpose of this study is to assess the efficacy of the buprenorphine transdermal patch (Norspan® or Sovenor® transdermal patch) in patients with chronic non-malignant pain of moderate to severe intensity due to osteoarthritis, rheumatoid arthritis, lower back pain and joint/muscle pain, who are not adequately responding to non-opioid painkillers.
A Multicentre, Randomised, Double-Blind, Parallel Group Comparison Of The Efficacy And Safety Of Transdermal Buprenorphine (Norspan'registered trade mark' Buprenorphine transdermal system [BTDS]) And Placebo In Patients With Diabetic Peripheral Neuropathic Pain.
100 项与 Mundipharma Pty Ltd. 相关的临床结果
0 项与 Mundipharma Pty Ltd. 相关的专利(医药)
100 项与 Mundipharma Pty Ltd. 相关的药物交易
100 项与 Mundipharma Pty Ltd. 相关的转化医学